Revance Therapeutics (RVNC) News Today $3.65 0.00 (0.00%) As of 02/6/2025 Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period RVNC Lawsuit Alert! Class Action Against Revance Therapeutics, Inc.February 21 at 4:38 PM | markets.businessinsider.comInvestors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNCFebruary 21 at 1:42 PM | globenewswire.comLost Money on Revance Therapeutics, Inc.(RVNC)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyFebruary 21 at 5:45 AM | prnewswire.comRVNC INVESTOR ALERT: Kirby McInerney LLP Reminds Revance Therapeutics, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action LawsuitFebruary 20 at 6:00 PM | globenewswire.comThe Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc. (RVNC) ShareholdersFebruary 20 at 1:17 PM | globenewswire.comThe Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc. (RVNC) ShareholdersFebruary 20 at 1:17 PM | globenewswire.comRevance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitFebruary 20 at 12:00 PM | prnewswire.comRevance Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNCFebruary 20 at 5:45 AM | prnewswire.comRevance Therapeutics (RVNC) Expected to Announce Earnings on WednesdayFebruary 19 at 3:30 AM | americanbankingnews.comRVNC STOCK NEWS: Robbins LLP Reminds Revance Therapeutics, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025February 18, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNCFebruary 18, 2025 | prnewswire.comRVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitFebruary 18, 2025 | globenewswire.comShareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights – RVNCFebruary 18, 2025 | globenewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNCFebruary 18, 2025 | prnewswire.comRevance Therapeutics (NASDAQ:RVNC) Research Coverage Started at StockNews.comFebruary 17, 2025 | americanbankingnews.comRevance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitFebruary 14, 2025 | prnewswire.comRevance Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNCFebruary 14, 2025 | prnewswire.comRevance Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights – RVNCFebruary 13, 2025 | globenewswire.comInvestors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNCFebruary 13, 2025 | prnewswire.comRVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitFebruary 12, 2025 | globenewswire.comInvestors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights – RVNCFebruary 12, 2025 | globenewswire.comRevance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitFebruary 12, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNCFebruary 11, 2025 | prnewswire.comMarch 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNCFebruary 11, 2025 | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Therapeutics, Inc. Lawsuit – RVNCFebruary 10, 2025 | globenewswire.comThe Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc.(RVNC) ShareholdersFebruary 10, 2025 | prnewswire.comCrown Laboratories Completes Acquisition of Revance TherapeuticsFebruary 7, 2025 | businesswire.comClass Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors – Contact Levi & KorsinskyFebruary 7, 2025 | globenewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNCFebruary 7, 2025 | prnewswire.comRVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitFebruary 6, 2025 | globenewswire.comThe Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc. (RVNC) ShareholdersFebruary 6, 2025 | globenewswire.comCrown Laboratories, Inc.: Crown Laboratories Announces Completion of Acquisition of Revance TherapeuticsFebruary 6, 2025 | finanznachrichten.deRevance Therapeutics sells to Crown LaboratoriesFebruary 6, 2025 | bizjournals.comRevance’s acquisition by Crown Laboratories completedFebruary 6, 2025 | markets.businessinsider.comCrown Laboratories Announces Completion of Acquisition of Revance TherapeuticsFebruary 6, 2025 | prnewswire.comThe Gross Law Firm Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming DeadlineFebruary 6, 2025 | prnewswire.comRevance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.comStockNews.com initiated coverage on shares of Revance Therapeutics in a research report on Thursday. They set a "hold" rating for the company.February 6, 2025 | marketbeat.comDeltec Asset Management LLC Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)Deltec Asset Management LLC purchased a new position in Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 100,000 shares of the biopharmaceutiFebruary 5, 2025 | marketbeat.comCrown Laboratories and Revance Therapeutics Announce Expiration of Tender OfferFebruary 5, 2025 | prnewswire.comRVNC INVESTOR ALERT: Kirby McInerney LLP Notifies Revance Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action LawsuitFebruary 4, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNCFebruary 4, 2025 | prnewswire.comLevi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming DeadlineFebruary 4, 2025 | globenewswire.comInvestors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNCFebruary 4, 2025 | prnewswire.comShareholders that lost money on Revance Therapeutics, Inc. ...February 3, 2025 | gurufocus.comShareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact The Gross Law Firm about pending Class Action - RVNCFebruary 3, 2025 | prnewswire.comRVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 31, 2025 | globenewswire.comRevance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJanuary 31, 2025 | prnewswire.comRevance Therapeutics, Inc. Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Losses Should Contact the Law Firm for More InformationJanuary 31, 2025 | globenewswire.comRevance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th DeadlineJanuary 31, 2025 | prnewswire.comShareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNCJanuary 31, 2025 | prnewswire.com Get Revance Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Email Address RVNC Media Mentions By Week RVNC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVNC News Sentiment▼0.000.60▲Average Medical News Sentiment RVNC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVNC Articles This Week▼156▲RVNC Articles Average Week Get Revance Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARQT News Today AMPH News Today IMCR News Today KNSA News Today DYN News Today GPCR News Today ARDX News Today INDV News Today NRIX News Today VIR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVNC) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revance Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
